









Markets
/
Stocks
/
nasdaq-zntl
/

Zentalis Pharmaceuticals Inc

ZNTL

1.320USD

-0.120-8.33%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

95.22MMarket Cap

LossP/E TTM



Zentalis Pharmaceuticals Inc

1.320

-0.120-8.33%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

More Details of Zentalis Pharmaceuticals Inc Company

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Zentalis Pharmaceuticals Inc Info



Ticker SymbolZNTL

Company nameZentalis Pharmaceuticals Inc

IPO dateApr 03, 2020

CEOMs. Julie Eastland

Number of employees166

Security typeOrdinary Share

Fiscal year-endApr 03

Address10275 Science Center Drive

CitySAN DIEGO

Stock exchangeNASDAQ Global Market Consolidated

CountryUnited States of America

Postal code92121

Phone18582634333

Websitehttps://www.zentalis.com/

Ticker SymbolZNTL

IPO dateApr 03, 2020

CEOMs. Julie Eastland

Company Executives of Zentalis Pharmaceuticals Inc



Name

Name/Position

Position

Shareholding

Change

Mr. David Michael Johnson

Independent Director

250.42K

+29.87%

Dr. Jan Skvarka, Ph.D.

Independent Director

194.95K

+41.94%

Dr. Enoch Kariuki, Pharm.D.

Independent Director

137.37K

+72.22%

Dr. Ingmar Bruns, M.D.

Chief Medical Officer

36.63K

Dr. Luke Walker, M.D.

Independent Director

Mr. Karan S. Takhar

Independent Director

Mr. Scott Myers

Independent Chairman of the Board

Ms. Julie Eastland

President, Chief Executive Officer, Director

Mr. James B. Bucher, J.D.

Chief Legal Officer and Corporate Secretary

Name

Name/Position

Position

Shareholding

Change

Mr. David Michael Johnson

Independent Director

250.42K

+29.87%

Dr. Jan Skvarka, Ph.D.

Independent Director

194.95K

+41.94%

Dr. Enoch Kariuki, Pharm.D.

Independent Director

137.37K

+72.22%

Dr. Ingmar Bruns, M.D.

Chief Medical Officer

36.63K

Dr. Luke Walker, M.D.

Independent Director

Mr. Karan S. Takhar

Independent Director

Revenue Breakdown

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2019

FY2018

No Data

By RegionUSD

Name

Revenue

Proportion

United States

0.00

0.00%

By Business

By Region

No Data

Shareholding Stats

Updated: Fri, Aug 15

Shareholders

Shareholder Types

Shareholders

Proportion

Matrix Capital Management Company, LP

19.35%

Walters (William T)

9.77%

The Vanguard Group, Inc.

4.00%

Acadian Asset Management LLC

3.88%

Two Sigma Investments, LP

3.28%

Other

59.71%

Shareholders

Proportion

Matrix Capital Management Company, LP

19.35%

Walters (William T)

9.77%

The Vanguard Group, Inc.

4.00%

Acadian Asset Management LLC

3.88%

Two Sigma Investments, LP

3.28%

Other

59.71%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

29.24%

Hedge Fund

20.73%

Investment Advisor

13.86%

Individual Investor

12.70%

Research Firm

5.57%

Venture Capital

2.88%

Corporation

1.32%

Endowment Fund

0.24%

Family Office

0.12%

Other

13.33%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

354

52.36M

72.58%

-28.24M

2025Q2

374

67.79M

93.98%

-24.60M

2025Q1

386

70.02M

97.36%

-19.46M

2024Q4

379

71.39M

100.17%

-15.78M

2024Q3

373

74.19M

104.47%

-21.21M

2024Q2

365

79.92M

112.67%

-23.64M

2024Q1

360

88.75M

125.22%

-9.75M

2023Q4

361

83.47M

118.17%

-13.77M

2023Q3

361

82.76M

117.68%

-11.58M

2023Q2

361

84.96M

121.10%

+6.07M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Matrix Capital Management Company, LP

13.96M

19.35%

Jun 30, 2025

Walters (William T)

7.05M

9.77%

+3.05M

+76.25%

Jan 29, 2025

The Vanguard Group, Inc.

2.88M

-375.98K

-11.53%

Jun 30, 2025

Acadian Asset Management LLC

2.80M

3.88%

+124.98K

+4.67%

Jun 30, 2025

Two Sigma Investments, LP

2.37M

3.28%

+977.03K

+70.19%

Jun 30, 2025

Opaleye Management Inc.

1.92M

2.67%

-60.70K

-3.06%

Jun 30, 2025

Almitas Capital LLC

1.60M

2.22%

-111.66K

-6.53%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.58M

2.2%

-2.25M

-58.69%

Jun 30, 2025

Tang Capital Management, LLC

1.55M

2.15%

+50.00K

+3.33%

Jun 30, 2025

Renaissance Technologies LLC

1.53M

2.12%

+703.51K

+85.17%

Jun 30, 2025

Related ETFs



Updated: Sun, Nov 2

Name

Proportion

Federated Hermes MDT Small Cap Core ETF

0.11%

iShares Micro-Cap ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Fidelity Enhanced Small Cap ETF

0.01%

Invesco Nasdaq Biotechnology ETF

Fidelity Fundamental Large Cap Growth ETF

T Rowe Price Small-Mid Cap ETF

Optimize Strategy Index ETF

Humankind US Stock ETF

Avantis US Equity ETF

Federated Hermes MDT Small Cap Core ETF

Proportion0.11%

iShares Micro-Cap ETF

Proportion0.02%

Invesco RAFI US 1500 Small-Mid ETF

Proportion0.01%

Fidelity Enhanced Small Cap ETF

Proportion0.01%

Invesco Nasdaq Biotechnology ETF

Proportion0%

Fidelity Fundamental Large Cap Growth ETF

Proportion0%

T Rowe Price Small-Mid Cap ETF

Proportion0%

Optimize Strategy Index ETF

Proportion0%

Humankind US Stock ETF

Proportion0%

Avantis US Equity ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

KeyAI

